Lexicon Pharmaceuticals, Inc. (LXRX) Position Lifted by Schwab Charles Investment Management Inc.

Schwab Charles Investment Management Inc. boosted its holdings in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 5.6% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 204,129 shares of the biopharmaceutical company’s stock after buying an additional 10,811 shares during the quarter. Schwab Charles Investment Management Inc.’s holdings in Lexicon Pharmaceuticals were worth $2,509,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in LXRX. Kornitzer Capital Management Inc. KS acquired a new position in Lexicon Pharmaceuticals during the 3rd quarter valued at about $9,420,000. State Street Corp increased its holdings in shares of Lexicon Pharmaceuticals by 19.9% in the second quarter. State Street Corp now owns 1,967,255 shares of the biopharmaceutical company’s stock valued at $32,363,000 after purchasing an additional 326,088 shares during the period. Voya Investment Management LLC increased its holdings in shares of Lexicon Pharmaceuticals by 21.7% in the second quarter. Voya Investment Management LLC now owns 875,577 shares of the biopharmaceutical company’s stock valued at $14,403,000 after purchasing an additional 156,345 shares during the period. Quantitative Investment Management LLC acquired a new position in shares of Lexicon Pharmaceuticals in the second quarter valued at about $2,304,000. Finally, FMR LLC increased its holdings in shares of Lexicon Pharmaceuticals by 0.9% in the second quarter. FMR LLC now owns 15,785,280 shares of the biopharmaceutical company’s stock valued at $259,668,000 after purchasing an additional 137,421 shares during the period.

A number of research analysts have recently weighed in on LXRX shares. Zacks Investment Research lowered Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, October 17th. ValuEngine lowered Lexicon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Sunday, December 31st. Finally, Wedbush reissued an “outperform” rating on shares of Lexicon Pharmaceuticals in a report on Thursday, October 5th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $28.50.

In related news, Director Public Equities L.P. Invus bought 180,727 shares of the company’s stock in a transaction that occurred on Friday, November 17th. The shares were purchased at an average cost of $10.11 per share, with a total value of $1,827,149.97. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Lonnel Coats bought 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 15th. The shares were bought at an average cost of $9.91 per share, for a total transaction of $99,100.00. Following the completion of the acquisition, the chief executive officer now owns 42,985 shares of the company’s stock, valued at $425,981.35. The disclosure for this purchase can be found here. Over the last ninety days, insiders have purchased 914,353 shares of company stock worth $8,916,253. 5.77% of the stock is owned by corporate insiders.

Lexicon Pharmaceuticals, Inc. (NASDAQ LXRX) opened at $10.17 on Thursday. The company has a quick ratio of 1.65, a current ratio of 1.66 and a debt-to-equity ratio of 1.09. The firm has a market capitalization of $1,036.87, a PE ratio of -8.07 and a beta of 0.10. Lexicon Pharmaceuticals, Inc. has a 1-year low of $8.07 and a 1-year high of $18.00.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.07. The business had revenue of $26.94 million for the quarter, compared to analyst estimates of $27.97 million. Lexicon Pharmaceuticals had a negative return on equity of 111.68% and a negative net margin of 165.69%. The company’s revenue was down 2.8% on a year-over-year basis. During the same period in the prior year, the company earned ($0.35) earnings per share. sell-side analysts anticipate that Lexicon Pharmaceuticals, Inc. will post -1.38 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This report was first published by Ticker Report and is the property of of Ticker Report. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at https://www.tickerreport.com/banking-finance/3144023/lexicon-pharmaceuticals-inc-lxrx-position-lifted-by-schwab-charles-investment-management-inc.html.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.

Want to see what other hedge funds are holding LXRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX).

Institutional Ownership by Quarter for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.